Academic Journal
Q1International Journal of Oncology
About International Journal of Oncology
About International Journal of Oncology
International Journal of Oncology is a peer-reviewed scholarly journal published by Spandidos Publications (Greece). It focuses on Q1. Publication coverage spans 1993-2026.
Key indicators: ISSN 1791-2423, 1019-6439; H-index 146.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (146): Exceptionally high — 146 articles have each been cited at least 146 times. This indicates deep, sustained influence in the field.
Publishing in International Journal of Oncology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of International Journal of Oncology?
1791-2423, 1019-6439.
Who publishes International Journal of Oncology?
Spandidos Publications.
What are International Journal of Oncology's metrics?
H-index 146.
Where do I submit to International Journal of Oncology?
Via the official website.
Is International Journal of Oncology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Cancer-related Molecular Pathways; RNA modifications and cancer; Cancer-related molecular mechanisms research; MicroRNA in disease regulation; Cancer, Hypoxia, and Metabolism; Cancer Cells and Metastasis.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
[Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Nikolaos Ioannou, Alan Seddon, Angus Dalgleish, David Mackintosh et al.
2026-10-09 · DOI: 10.3892/ijo.2026.5948Comprehensive landscape and future perspectives of PIWI‑interacting RNAs in cancer (Review)
Xiaoqian Yu, Changlong Li, Tongtao Zhuang, Siqing Sun et al.
2026-10-09 · DOI: 10.3892/ijo.2026.5946Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review)
Chuanyang Lu, Tingting Zhou, Wenxin Zhang, Lulu Wei et al.
2026-10-09 · DOI: 10.3892/ijo.2026.5947Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)
Ieva Norkaityte, Laura Racyte, Egle Balciunaite, Aiste Avizaite et al.
2026-10-08 · DOI: 10.3892/ijo.2026.5945cGAS‑STING pathway in digestive tract cancer: From molecular mechanisms to therapeutic applications (Review)
Tangna Chen, Jingyi Zhang, Jinghan Sun, Hongyan Zhang et al.
2026-10-07 · DOI: 10.3892/ijo.2026.5944Regulatory T cells in lung adenocarcinoma: Mechanisms of immune escape, prognostic significance and therapeutic opportunities (Review)
Lijuan Wang, Chenjin Ruan
2026-10-06 · DOI: 10.3892/ijo.2026.5943[Retracted] In vitro modulation of MMP‑2 and MMP‑9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors
M.W. Roomi, T. Kalinovsky, J. Monterrey, M. Rath et al.
2026-09-21 · DOI: 10.3892/ijo.2026.5942Eomesodermin in renal cell carcinoma: Epigenetic and immune crosstalk driving tumor progression (Review)
Zhifei Che, Dongwen Huang, Jiaming Lin, Xincen Wang et al.
2026-09-18 · DOI: 10.3892/ijo.2026.5941E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway
Ye Liang, Jie Zhuang
2026-09-16 · DOI: 10.3892/ijo.2026.5939[Expression of Concern] Ultraviolet exposure of melanoma cells induces fibroblast activation protein‑α in fibroblasts: Implications for melanoma invasion
Petra Wäster, Inger Rosdahl, Brendan Gilmore, Oliver Seifert et al.
2026-09-16 · DOI: 10.3892/ijo.2026.5940[Corrigendum] TIP60 governs the auto‑ubiquitination of UHRF1 through USP7 dissociation from the UHRF1/USP7 complex
Tanveer Ahmad, Waseem Ashraf, Abdulkhaleg Ibrahim, Liliyana Zaayter et al.
2026-09-14 · DOI: 10.3892/ijo.2026.5938[Corrigendum] miR‑221/222 promote malignant progression of glioma through activation of the Akt pathway
Junxia Zhang, Lei Han, Youlin Ge, Xuan Zhou et al.
2026-09-03 · DOI: 10.3892/ijo.2026.5937Dendritic cell‑based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)
Lian Pong, Siti Hassanudin, Seng Tham, Ravichandran Manickam et al.
2026-09-03 · DOI: 10.3892/ijo.2026.5936MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review)
Zhao Yiming, Li Jie
2026-09-02 · DOI: 10.3892/ijo.2026.5934[Retracted] Pro‑metastatic intracellular signaling of the elaidic trans fatty acid
Kiyomu Fujii, Yi Luo, Rina Fujiwara-tani, Shingo Kishi et al.
2026-09-02 · DOI: 10.3892/ijo.2026.5935Effect of xeroderma pigmentosum group C on the characteristics and regulatory mechanisms of lung cancer stem cells
Ben Yang, Yang Yang, Weiyu Wang, Yubing Wang et al.
2026-09-01 · DOI: 10.3892/ijo.2026.5933Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)
Jinghao Pan, Boyang Li, Ruonan Lin, Chenlu Fang et al.
2026-08-21 · DOI: 10.3892/ijo.2026.5932[Corrigendum] Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
Michal Pastorek, Veronika Simko, Martina Takacova, Monika Barathova et al.
2026-08-20 · DOI: 10.3892/ijo.2026.5931Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer
Tao Pan, Zujian Feng, Ting Shang, Jun Jiang et al.
2026-08-19 · DOI: 10.3892/ijo.2026.5930KIAA1429 knockdown alleviates osteosarcoma progression by destabilizing SLC7A11 mRNA via m6A methylation to promote ferroptosis
Hui Zeng, Yunyan Zhong, Dingbiao Zeng, Shiliang Xiao et al.
2026-08-17 · DOI: 10.3892/ijo.2026.5929Reviews
Community Reviews
Version History
October 9, 2026 at 7:32 pm
September 25, 2026